Publications by authors named "F Matzkies"
Article Synopsis
- The study aimed to evaluate the safety and efficacy of filgotinib, a JAK1 preferential inhibitor, in Japanese patients who had an inadequate response to methotrexate (MTX) over 52 weeks.
- Patients were randomly assigned to receive either filgotinib or adalimumab while continuing stable doses of MTX, with efficacy assessed at various intervals and safety monitored through adverse event reporting.
- Results showed that filgotinib maintained efficacy and safety over the one-year period, with adverse events remaining consistent when compared to the overall population, indicating its potential as a viable treatment option.
Article Synopsis
- The study aimed to assess the safety and effectiveness of filgotinib, lanraplenib, and tirabrutinib in patients with active Sjögren's Syndrome (SS).
- In a double-blind trial involving 150 patients, primary outcomes were based on improvement criteria assessed at week 12, with no notable differences among the treatment groups compared to placebo.
- Although primary and secondary endpoints were not met, some subgroup results and biomarker reductions suggest potential for these drugs, highlighting the need for further research.
Objective: Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib (FIL) in Japanese patients with moderately to severely active rheumatoid arthritis (RA).
Methods: Data from three Phase 3 trials (NCT02889796, NCT02873936, and NCT02886728) and a long-term extension (NCT03025308) through September 2019 were integrated; patients received ≥1 dose of FIL 200 (FIL200) or 100 mg (FIL100) daily, or placebo (PBO). We calculated exposure-adjusted incidence rates (EAIRs) per 100 patient-years FIL exposure (100PYE) for treatment-emergent adverse events (TEAEs) and adverse events of special interest.
Article Synopsis
- The study assessed the effectiveness and safety of filgotinib, a Janus kinase-1 inhibitor, in Japanese rheumatoid arthritis patients who didn't respond well to methotrexate.
- In a 52-week study of 147 patients, filgotinib showed higher American College of Rheumatology response rates and better disease control compared to adalimumab and placebo after 24 weeks.
- Treatment was generally safe, with low rates of serious infections and no deaths, indicating filgotinib's potential as a beneficial therapy for this patient group.
Objective: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis.
Methods: Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308). Results are from placebo (PBO)-controlled (through week (W)12) and long-term, as-treated (all available data for patients receiving ≥1 dose filgotinib 200 (FIL200) or 100 mg (FIL100) daily) datasets.